From the American Academy of Ophthalmology

Investigators analyzed data from the BRAVO and CRUISE trials to determine if the visual acuity achieved with regular ranibizumab treatment for branch retinal vein occlusion or central retinal vein occlusion translated to improved reading speed. Mean gain in the treated group was 31.3 wpm compared with 15.0 wpm in sham-treated eyes (P=.007) at 6 months. A gain of 15 or more letters of best corrected visual acuity letter score corresponded to an increase in reading speed of 12.3 wpm and 15.8 wpm in patients with branch and central RVO, respectively. JAMA Ophthalmology, May 2013